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The binding of affinity-purified anticardiolipin
antibodies (ACA) to liposomes that contained
cardiolipin or phosphatidylserine was investi-
gated. ACA bound to these liposomes only in the
presence of plasma or serum, which indicated a
requirement for a plasma component. This compo-
nent&mdash;referred to as aca-cofactor&mdash;was purified;
its activity to support ACA binding to liposomes
that contained cardiolipin was not destroyed by
heat (10 min at 90&deg;C), but was greatly diminished
on incubation with trypsin. aca-cofactor bound
liposomes that contained negatively charged
phospholipid but had no affinity for liposomes that
contained neutral phospholipid (eg, phospha-
tidylcholine); this binding was independent of
calcium ions. aca-cofactor was essential for ACA
to bind to liposomes that contained cardiolipin or
phosphatidylserine and, when coated on a micro-
titre plate in the absence of any phospholipid,
aca-cofactor was an apparent antigen for ACA in
an enzyme-linked immunosorbent assay. aca-co-
factor is a single chain polypeptide with an
apparent molecular weight of 50 kD (non-re-
duced), which increases to 70 kD upon reduction,
and its properties closely resemble those of
&bgr;2-glycoprotein I (apolipoprotein H).
Lancet 1990; 335: 1544-47.
Introduction
Anticardiolipin antibodies (ACA) and lupus anticoagulants
(LAC) are closely related autoantibodies, which may be
found in the plasma of patients with systemic lupus
erythematosus (SLE), other immunological, neoplastic, or
infective disorders, and apparently normal people with no
evidence of underlying disease.’ Some 30% of people who
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have these antibodies suffer from arterial or venous
thrombosis, thrombocytopenia, and repeated abortions.1
ACA and LAC are detected because they react with
negatively-charged phospholipids (eg, phosphatidic acid,
cardiolipin, phosphatidylserine, and phosphatidylinositol)
in immunoassays2,3 and because they prolong phospholipid-
dependent clotting tests in vitro.4
In 1959, LoeligerS observed that some plasma samples
showed enhanced LAC activity when mixed with normal
plasma; the concept of LAC cofactor was introduced, and
prothrombin was suggested to represent this cofactor.5 In
1965, LAC cofactor was localised in the gammaglobulin
fraction of both normal and LAC plasma.6 Rivard et al7
showed that LAC cofactor was neither prothrombin nor a
gammaglobulin but a different molecule with an apparent
molecular weight of 200 kD’-although it has also been
suggested that the cofactor is a laboratory artifact.8 We have
purified and characterised a protein, termed aca-cofactor,
which is found in normal plasma, and is required for the
expression of ACA activity.
Materials and methods
We studied plasma from 2 men found to be seropositive for both
ACA and LAC on routine investigation by enzyme-linked
immunoassays (ELISAs). One patient, aged 39, had had repeated
peripheral thrombosis; the other, aged 51, had had recurrent
thrombosis of cerebral and renal arterioles. Neither had any other
feature to suggest a diagnosis of SLE.9 ACA were purified by a
modification of the method described by Pengo et al.1o Briefly, a
mixture of cardiolipin, phosphatidylcholine, and cholesterol (molar
ratio 2-5:10:4, respectively; all from Sigma, St Louis, Missouri,
USA) in ethanol was dried under a stream of nitrogen. The lipids
were resuspended directly in the plasma of the patients to a final
cardiolipin concentration of 3 mg/ml. After incubation at 37&deg;C for
1 h the mixture was diluted 1:4 in "tris"-buffered saline (TBS; 0,05
mol/1 tris, 0-1 1 mol/I NaCl, pH 7-4) and centrifuged at 20000 g for 15
min at 10&deg;C. The precipitate was washed 3 times with TBS and the
liposomal pellet was dissolved in a 2% (w/v) solution of n-octyl-p-
D-glucopyranoside (Sigma) in TBS so that the final concentration
of cardiolipin was 3 mg/ml. This mixture was applied to a column of
protein A-’sepharose CL 4B’ (Pharmacia Fine, Uppsala, Sweden).
After extensive washing with 2% octylglucoside to remove the
lipids, followed by washing with TBS, the bound IgG was eluted
with 1 mol/1 acetic acid, and the eluates were immediately
neutralised by 3 mol/1 "tris". Fractions that contained IgG were
pooled and dialysed against TBS before they were tested for ACA
content.
The ELISA for ACA essentially followed the procedure of
Loizou et al. Briefly, microtitre plates were coated with cardiolipin
(30 ul of a 50 Ilgjml solution of cardiolipin in ethanol per well). After
evaporation of the solvent, followed by washing with PBS,
non-specific binding sites were blocked with 10% bovine serum
albumin (Sigma) in PBS for 1 h. Samples that contained ACA were
diluted in 10% bovine serum in PBS and subsequently applied to
the wells. The amount of ACA bound was assessed by incubation
with peroxidase-conjugated goat anti-human IgG. After reaction of
peroxidase with chromogenic substrate (tetramethylbenzidine) the
optical density at 450 nm (OD 450) was measured.
ACA BINDING TO LIPOSOMES IN PRESENCE OF PLASMA OR
PURIFIED ACA-COFACTOR
CL = cardiolipin; PC=phosphatidylcholine; Choi = cholesterol, PS=phospha-
tidyiserine
To determine binding affinity to liposomes, 25 jil ACA were
mixed with 50 N1 cardiolipin:phosphatidylcholine:cholesterol
(molar ratio 2-5:10:4) liposomes in the presence of 125 N1 plasma,
TBS, or other test materials. Final concentrations were 125 jlg/ml
and 750 )ig/ml for ACA and cardiolipin, respectively; aca-cofactor
was used at a final concentration of 300 (ig/ml. After 30 min
incubation at 37&deg;C mixtures were centrifuged at 100 000 g for 15
min and supernatants were evaluated for residual ACA activity by
the standard ELI SA described above. Data are calculated according
to the formula:
ACAjgj &mdash; ACAp.  100%
ACArotal
In some experiments liposomes were used in which cardiolipin was
replaced by phosphatidylserine at a molar ratio for phospha-
tidylserine :phosphatidylcholine :cholesterol of 5:10:4 to correct
for the difference in nett charge between cardiolipin and
phosphatidylserine or by phosphatidylcholine at a molar ratio
for phosphatidylcholine:cholesterol of 15:4.
aca-cofactor was purified from plasma by ammonium sulphate
precipitation (50%-90% saturation) followed by ion-exchange
chromatography on ’QAE-Sephadex’ in 50 mmol/1 "tris" buffer at
pH 74. The column was eluted by a salt-gradient and aca-cofactor
activity was recovered at 100 mmol/1 NaCl. Sodium dodecyl-
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was
done on a 7-5% polyacrylamide gel with a 4% polyacrylamide
stacking gel; after electrophoresis the gel was stained with coomassie
brilliant blue. Protein content of samples was assayed according to
Sedmak and Grossberg.11
Results and discussion
Affinity-purified ACA from the plasma of both patients
reacted strongly with cardiolipin in a lipid-based ELISA.
Binding was little changed by substitution of cardiolipin by
phosphatidylserine, whereas binding of affinity-purified
ACA was abolished with phosphatidylcholine-coated wells
(data not shown). In direct binding experiments, in which
ACA were incubated with liposomes composed of a mixture
of cardiolipin, phosphatidylcholine, and cholesterol in TBS,
the 100 000 g supernatant of this incubation still contained
100% ACA activity-which indicated no ACA binding to
liposomes. Replacement of TBS by normal plasma reduced
ACA activity in the supernatant to less than 5% (table),
Fig 1-ACA binding to immobilised cardiolipin at different
concentrations of normal plasma.
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Fig 2-Binding of ACA and/or aca-cofactor to liposomes that
contain cardiolipin.
Lanes 1 & 2: ACA with liposomes; lanes 3 & 4: ACA and aca-cofactor
with liposomes; lanes 5 & 6: aca-cofactor with liposomes.
Lanes 1, 3, and 5 represent proteins in the supernatant, lanes2,4, and 6
represent proteins in the liposomal pellet.
and a similar result was obtained when phosphatidylserine
was substituted for cardiolipin. No ACA binding was found
to liposomes composed of phosphatidylcholine and
cholesterol. These findings indicate that a plasma
component is involved in the binding of ACA to liposomes
that contain negatively charged phospholipids, as suggested
by McNeil et al,12 who also observed that binding of purified
antiphospholipid antibodies to immobilised phospholipid
required the presence of plasma.
In the standard ELISA for ACA, different dilutions of
the antibody-containing samples are routinely made in 10%
bovine serum in TBS; the same medium is also used during
the binding-step of ACA to the cardiolipin-coated wells of
the microtitre plates. We found that bovine serum could be
replaced by bovine plasma, human serum, or human
plasma, but not by purified bovine or human serum
albumin. To further investigate the role of plasma in ACA
binding to cardiolipin, the standard ELISA was modified.
Instead of dilution in 10% bovine serum, constant amounts
of ACA were mixed with dilutions of normal pooled plasma
and applied to the well. Microtitre plates were further
processed as described for the standard ELI SA. Fig 1 shows
the OD 450 as a function of the plasma concentration: a
linear correlation between OD and plasma concentrations is
observed from 0 to 05%, where a plateau is reached; similar
findings were obtained with human serum and bovine
plasma or serum. Thus a plasma component
Fig 3-IgG binding to microtitre plates coated with aca-
cofactor in absence of phospholipid.
3 = affinity purified anticardiolipin IgG (17 &micro;g/ml).
#=normal (non-specific) IgG (133)&micro;g/ml).
Concentration of undiluted aca-cofactor was 300 I1g/ml.
is necessary for ACA binding to immobilised cardiolipin.
This plasma component, termed aca-cofactor, can be
detected and measured by this modified ELISA by
comparison with a calibration curve as shown in fig 1.
The final step in the purification of aca-cofactor involves
heat treatment (10 min at 90&deg;C) followed by centrifugation
to remove denatured protein material. No loss of aca-
cofactor activity occurred in this step, but when the
preparation obtained was incubated with trypsin, aca-
cofactor became inactive. SDS-PAGE showed aca-cofactor
to be a single-chain polypeptide with an apparent molecular
weight of 50 kD (non-reduced) which increased to 70 kD
upon reduction. The specific activity of the cofactor
preparation was 350 times that of crude plasma; if 100%
purity of this preparation was assumed the plasma
concentration of aca-cofactor would be approximately 02
mg/ml.
Purified aca-cofactor was used to study the interaction of
affinity-purified ACA with liposomes (see table). aca-
cofactor can be substituted for plasma without loss of
binding of ACA to liposomes that contained negatively-
charged phospholipid. Both supernatant and pellet of the
binding experiments with purified aca-cofactor and/or ACA
were analysed by SDS-PAGE as shown in fig 2 for samples
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obtained after incubations with cardiolipin-containing
liposomes; similar results are obtained with liposomes that
contained phosphatidylserine. No binding of either of the
proteins was observed with liposomes without negatively-
charged lipids. Without cofactor, no IgG was detectable in
the 100 000 g pellet of the incubations (lanes 1, 2); with
cofactor, approximately 60-70% of the IgG co-sediments
with the liposomes (lanes 3, 4). Incomplete binding of IgG
was not due to a limiting amount of aca-cofactor and the
unbound fraction of IgG in the 100 000 g supernatant no
longer contained any ACA activity, so the IgG fraction
isolated from the plasma presumably contains antibodies
other than ACA with non-specific binding to the liposomes
used in the affmity purification procedure, or antibodies
directed against other lipid-binding proteins in plasma.
Fig 2 shows that aca-cofactor also binds to liposomes that
contain cardiolipin in the absence of IgG (lanes 5, 6).
Binding of aca-cofactor is not dependent on or inhibited by
the presence of calcium ions, so it is unlikely that binding is
mediated by y-carboxyglutamic acid residues on the
cofactor. We investigated the direct interaction between
aca-cofactor and affinity-purified ACA in an ELISA in
which the microtitre plates were coated with different
amounts of cofactor. After coating, a fixed amount of ACA
or normal IgG was applied to the wells in the absence of
phospholipid. ACA binding was proportional to the amount
of aca-cofactor in the wells (fig 3) and no binding was found
with normal human IgG. Thus anticardiolipin antibodies of
at least these two patients are not directed against cardiolipin
but against a protein with a high affinity for negatively-
charged phospholipid surfaces.
It is remarkable that the cofactor is not co-purified during
the affinity purification of ACA via cardiolipin-containing
liposomes. Two possible explanations might account for
this: ACA only recognises aca-cofactor when bound to lipid
or absorbed on a microtitre plate; or aca-cofactor undergoes
structural modification upon addition of octylglucoside
during ACA purification. Although aca-cofactor is present
in normal human (and bovine) plasma in concentrations of
up to 02 mg/ml, its identity is still obscure. The heat
stability and behaviour on SDS-PAGE (increase in
apparent molecular weight upon reduction) suggest the
presence of several disulphide bridges. Preliminary
experiments with purified coagulation factors indicate that
binding of aca-cofactor to negatively-charged phospholipid
surfaces interferes with binding of the prothrombin
activating complex factor Xa-factor Va, leading to a
diminished rate of thrombin formation. Thus ACA may be
directed against a naturally circulating anticoagulant with
high affinity towards negatively-charged phospholipid
surfaces.
The high purity of the aca-cofactor allows analysis of
aminoacid composition, which is under investigation.
However the properties so far identified (molecular weight
50 kD [non-reduced], 70 kD [reduced with 5%
&bgr;-mercaptoethanol]; estimated plasma concentration 200
&micro;g/ml; heat stability; calcium-independent binding to
anionic phospholipids; support of ACA binding to anionic
phospholipids; and inhibition of phospholipid-dependent
coagulation reactions) are very similar to those of
&bgr;2-glycoprotein I (apolipoprotein H), the anticoagulant
properties of which we have previously described.13
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From The Lancet
Medical examinations
The qualified practitioners of the present day are all members of
medical corporations. Are they to have anything to do with the
management of those corporations? Are twenty-one, or any other
number, of self-elected, irresponsible gentlemen in London,
Dublin, or Edinburgh, to appropriate the public money, expend it
as they please, dispose of the property, power, patronage, and
interests of twenty or thirty thousand enlightened men scattered
over the United Kingdom? Have the physicians, surgeons, general
practitioners of the United Kingdom no fair claim to the franchise?
Are they to be mocked for ever by the Councils of their own
Institutions, and to be trampled under foot by the Poor-Law
Commissioners, or by any other class of men, from the want of the
energy and protection which a united, well-organised,
representative corporation would give? Does any one mean to
assert, that the present generation of practitioners is unworthy of a
free constitution; that we do not understand our own interests and
rights; or are so besotted as to be incapable of selecting
representatives who would promote science, study the public good,
and uphold the honour of the profession? Are we to sow all for the
next generation, and to reap nothing? Are our successors to surpass
us so immeasurably, because they undergo a uniform examination?
Our faith in the qualifications of the present race of practitioners is
great. They have become what they are, intelligent, efficient,
high-minded, in spite of the worst examinations, and the worst
means of education that were ever devised by the ingenuity or
wickedness of man.
(8 August 1840)
